MilliporeSigma News
-
MilliporeSigma Announces Siren Biotechnology As Winner Of Its North American Advance Biotech Grant
6/4/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced today that Siren Biotechnology has been selected as the North American winner of its 13th Advance Biotech Grant Program. The biotechnology startup, which is headquartered in San Francisco, California, USA, was selected for the development of its universal adeno-associated virus (AAV) immuno-gene therapy for cancer.
-
MilliporeSigma Expands Its Optimized VirusExpress® Platform For Lentiviral Vectors, Further Enhancing Quality And De-Risking Cell And Gene Therapy Manufacturing
5/8/2024
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, is pleased to announce the expansion of its VirusExpress® platform used in the development and manufacturing of lentiviral vectors.
-
MilliporeSigma Accelerates Readiness Of Bioprocessing Facility Of The Future
4/30/2020
MilliporeSigma today unveiled the next component of its BioContinuum™ Platform, the Bio4C™ Software Suite, creating a first-of-its-kind ecosystem that combines process control, analytics and plant-level automation. This transformative software suite will allow users to look across the entire manufacturing process versus individual operational units, giving biomanufacturers complete process control and deep insights, bringing Bioprocessing 4.0 to the here and now.